For immediate release |
12 January 2011 |
("Alliance" or the "Company")
Pre-close Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to report good trading in the second half of 2010. As a result the Company expects to report turnover for the full year to 31 December 2010 of close to £50m, an increase of approximately 60% on the previous year. Pre-tax profits for 2010 are expected to be slightly ahead of current market expectations.
Alliance Pharma's preliminary results for the year to 31 December 2010 are scheduled to be released on 23 March 2011.
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive Officer |
|
Richard Wright, Finance Director |
|
www.alliancepharma.co.uk |
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Simon Blank |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.